Published in Nat Rev Clin Oncol on July 10, 2012
Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 1.07
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost (2015) 0.86
Platelet effects on ovarian cancer. Semin Oncol (2014) 0.82
The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol (2014) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. Int J Clin Exp Pathol (2015) 0.78
Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis. J Am Assoc Lab Anim Sci (2014) 0.76
Multiple hypercoagulability disorders at presentation of non-small-cell lung cancer. Tuberc Respir Dis (Seoul) (2014) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med (1999) 6.88
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
Mechanisms of thrombus formation. N Engl J Med (2008) 4.67
Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med (2000) 4.51
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med (1998) 4.41
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer (2007) 4.22
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med (2006) 4.10
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 3.83
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost (2004) 3.36
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost (2007) 3.22
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) (1999) 2.85
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol (2005) 2.53
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol (2004) 2.43
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med (1990) 2.32
Prediction of venous thromboembolism in cancer patients. Blood (2010) 2.31
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol (2006) 2.23
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol (2003) 2.13
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med (2006) 2.02
Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost (2002) 1.99
Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol (2005) 1.96
Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol (2007) 1.92
Role of tissue factor in cancer. J Clin Oncol (2009) 1.91
Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med (2005) 1.90
Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol (2006) 1.89
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res (2007) 1.87
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Cancer and the prothrombotic state. Lancet Oncol (2002) 1.74
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer (2007) 1.60
Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev (2008) 1.58
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol (1989) 1.56
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med (2008) 1.54
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
Venous thromboembolism in ovarian cancer. Gynecol Oncol (2007) 1.42
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol (2003) 1.41
The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med (1988) 1.39
Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg (1995) 1.38
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica (2004) 1.38
The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost (2006) 1.35
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Chemotherapy-induced thrombosis. Thromb Res (2006) 1.34
Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer (1984) 1.32
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med (2004) 1.26
Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer (2009) 1.25
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc (2006) 1.20
Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost (2011) 1.20
Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer (1997) 1.20
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost (2003) 1.16
Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med (1998) 1.16
Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J (2002) 1.14
Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist (2003) 1.13
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer (2011) 1.12
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost (2012) 1.10
Routine heparin for patients with cancer? One answer, more questions. N Engl J Med (2012) 1.09
Venous thromboembolism in patients with active cancer. Thromb Haemost (2007) 1.09
Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost (2002) 1.08
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol (2003) 1.02
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica (2008) 1.00
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol (2011) 1.00
Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol (2003) 0.99
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med (2012) 5.25
The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract (2011) 3.79
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67
Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol (2011) 3.50
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol (2003) 2.77
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol (2012) 2.17
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Clinical features of bladder cancer in primary care. Br J Gen Pract (2012) 1.89
The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal (2010) 1.72
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol (2005) 1.69
Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest (2010) 1.67
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Pathways to the diagnosis of colorectal cancer: an observational study in three UK cities. Fam Pract (2005) 1.59
Acute infective conjunctivitis in primary care: who needs antibiotics? An individual patient data meta-analysis. Br J Gen Pract (2011) 1.59
Development and evaluation of a brief self-completed family history screening tool for common chronic disease prevention in primary care. Br J Gen Pract (2013) 1.45
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost (2010) 1.39
Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord (2011) 1.36
The surgical management of sacral chordomas. Spine (Phila Pa 1976) (2009) 1.24
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost (2010) 1.21
Will widgets and semantic tagging change computational biology? PLoS Comput Biol (2010) 1.21
Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol (2005) 1.19
Prospective study of elderly people comparing treatments following first primary care consultation for a symptomatic hip or knee. Fam Pract (2004) 1.14
Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol (2012) 1.14
S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol (2009) 1.13
Impact of persistent hip or knee pain on overall health status in elderly people: a longitudinal population study. Arthritis Rheum (2005) 1.12
Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H(2)S production. Antioxid Redox Signal (2010) 1.10
Clinical features of kidney cancer in primary care: a case-control study using primary care records. Br J Gen Pract (2013) 1.09
Views of cancer care reviews in primary care: a qualitative study. Br J Gen Pract (2011) 1.08
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res (2007) 1.08
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol (2012) 1.06
Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains. FASEB J (2004) 1.06
Retroperitoneal myolipoma. World J Surg Oncol (2005) 1.05
Population survey comparing older adults with hip versus knee pain in primary care. Br J Gen Pract (2005) 1.05
Hypoxia-inducible factor-1α is involved in the pro-angiogenic effect of hydrogen sulfide under hypoxic stress. Biol Pharm Bull (2010) 1.03
Diagnosis using "test of treatment". BMJ (2009) 1.03
Current status of pulmonary embolism in general surgery in Japan. Surg Today (2004) 1.00
Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol (2012) 1.00
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost (2012) 0.98
In the absence of evidence, who chooses? A qualitative study of patients' needs after treatment for colorectal cancer. J Health Serv Res Policy (2004) 0.97
Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol (2010) 0.96
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J (2013) 0.95
Intrathoracic fracture-dislocation of the proximal humerus: a case report and report of a new surgical technique. J Trauma (2007) 0.95
Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery. Skull Base (2010) 0.94
The Coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition: role of mitcohondrial [correction mitochondrial] complex III. J Biol Chem (2003) 0.94
"I wish I'd told them": a qualitative study examining the unmet psychosexual needs of prostate cancer patients during follow-up after treatment. Patient Educ Couns (2010) 0.94
Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet (2010) 0.92
Partners and close family members of long-term cancer survivors: health status, psychosocial well-being and unmet supportive care needs. Psychooncology (2011) 0.92
Hydrogen sulfide is an endogenous regulator of aging in Caenorhabditis elegans. Antioxid Redox Signal (2013) 0.92
Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol (2002) 0.91
Hypochlorous acid-mediated mitochondrial dysfunction and apoptosis in human hepatoma HepG2 and human fetal liver cells: role of mitochondrial permeability transition. Free Radic Biol Med (2005) 0.90
DISCERN-Genetics: quality criteria for information on genetic testing. Eur J Hum Genet (2006) 0.89
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes (2015) 0.88
Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol (2005) 0.88
The pro-inflammatory oxidant hypochlorous acid induces Bax-dependent mitochondrial permeabilisation and cell death through AIF-/EndoG-dependent pathways. Cell Signal (2006) 0.87
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost (2007) 0.87
Improving Practices in US Hospitals to Prevent Venous Thromboembolism: lessons from ENDORSE. Am J Med (2010) 0.87
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol (2008) 0.86
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther (2013) 0.84
Oncologic conditions that simulate common sports injuries. J Am Acad Orthop Surg (2014) 0.84
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol (2003) 0.84
Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev (2002) 0.83
Bowel cancer screening in England: a qualitative study of GPs' attitudes and information needs. BMC Fam Pract (2006) 0.83
Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: identification of the second HPS7 mutation in a patient presenting late in life. Thromb Haemost (2013) 0.83
Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther (2013) 0.82
Pain and overall health status in older people with hip and knee replacement: a population perspective. J Public Health (Oxf) (2006) 0.82
Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost (2005) 0.81
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer (2014) 0.80
Nitrite-mediated protection against hypochlorous acid-induced chondrocyte toxicity: a novel cytoprotective role of nitric oxide in the inflamed joint? Arthritis Rheum (2003) 0.80
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost (2015) 0.80
Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother (2014) 0.79
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. Obstet Gynecol Int (2013) 0.79
Venous thromboembolism pharmacologic prophylaxis after major surgery--are we doing well or not well enough? Ann Surg (2011) 0.79
Venous thromboembolism in laparoscopic surgery. Curr Opin Pulm Med (2003) 0.78
More on thromboprophylaxis: quantifying risk for venous thromboembolism. Thromb Haemost (2009) 0.78
beta-Phenylethyl isothiocyanate mediated apoptosis: a proteomic investigation of early apoptotic protein changes. Proteomics (2005) 0.78
Venous thromboembolism and cancer. Curr Probl Surg (2007) 0.77
Primary squamous cell carcinoma of the endometrium: two cases and a review of the literature. Diagn Cytopathol (2012) 0.77
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2004) 0.77
Thromboprophylaxis. J Neurosurg (2002) 0.75
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis. Oncology (Williston Park) (2003) 0.75
Contaminated heparin. N Engl J Med (2008) 0.75
Is quinsy often managed in the community? Br J Gen Pract (2002) 0.75
Inhibition of hypochlorous acid-induced oxidative reactions by nitrite: is nitrite an antioxidant? Biochem Biophys Res Commun (2003) 0.75